Southern California Regional
Molecular and Cytogenetics Meeting Recap
Selects NxClinical Software
for Newborn Screening & Genomic Testing Services.
Nexus Copy Number
Simple yet powerful tools for copy number (CNV) and sequence variation analysis and visualization from aCGH, SNP array, and NGS technologies (WES, WGS, targeted panels).
The Power of One
A comprehensive software system for genetic data analysis and management for clinical labs, designed to improve productivity and patient care.
BioDiscovery Research and Clinical Software
Innovative genomic software tools to empower clinical & research labs to make the world a healthier place.Learn More
Adoption of the NxClinical software has provided an efficient and secure workflow for our data batch loading and processing at our high volume clinical laboratory.
- Dr. Karine Hovanes, PhD, FACMG, Vice President of Scientific Advancement and Laboratory Director, Invitae
We were eager to be part of the Early Access program and try out NxClinical 4.1 Beta. We have been using NxClinical for many years and each release has features that we find really useful. BioDiscovery has also been very receptive to feedback from us on feature requests and we are happy to see many of those implemented in version 4.1 as they make our interpretation process even easier.
- Dr. Sharon Mexal, Senior Director of Clinical Operations, Ambry Genetics
Nexus Copy Number is a powerful tool in our workflow, allowing direct visualization of data from numerous platforms, with a graphical interface that is as appealing as it is informative.
- Dr. Matthew Breen, Professor, Genomics, Oscar J. Fletcher Distinguished Professor, Comparative Oncology Genetics
We have been using Nexus Copy Number and very happy with it. It allows direct visualization of data from different platforms with informative graphical interfaces. We integrated this powerful tool in our workflow.
- Dr. Yajuan Liu, Assistant Professor, Department of Pathology, University of Washington
My CAP/CLIA clinical lab has used BioDiscovery CNV software since 2012. I have evaluated many CNV analysis software programs and the BioDiscovery software always has been the best choice for my lab. I have watched the progression of their software development from Nexus Copy number to NxClinical 4.1 and have always been satisfied with their improvements. BioDiscovery listens to their customers and utilizes this information to improve and refine their software for clinical laboratories. NxClinical 4.1 continues to be intuitive to use, has a searchable database, and has new desirable features. I now use NxClinical 4.1 to analyze CNV data from the CytoScan XON array. I am able to define gene panels and only analyze the genes from a targeted list. Also, I like that NxClinical can be used to analyze NGS data to make CNV calls and I am in the process of evaluating this new feature.
- Todd Ackely, Manager, Michigan Molecular Genetics Laboratory (MMGL)
At the UCSD clinical genetics lab, we are tasked with providing a complete and clinically actionable genomic profile of a patient's tumor. NxClinical allows us to do this rapidly and comprehensively by allowing us to consider CNV, LOH, and sequence variants together within a single software. The combined analysis facilitates interpretation in particular with double hit events while allowing us to save resources. In addition, the ability of NxClinical to call CNVs from NGS is an added bonus that will allow us to replace multiple assays with a single NGS assay for interrogation of all genomic variants.
- Dr. Sarah Murray, Director of Genomics Technologies, UC San Diego
The functionality of NxClinical has allowed us to simplify and standardize our interpretation of CNVs across our group of Directors. This significantly reduces the time required to review the 10+ variants identified per genome.
- Dr. Lawrence Jennings, MD, PhD, Director, HLA and Molecular Diagnostic Labs at Northwestern Medicine
Who We Work With
April 5-7, 2019Events
April 5-7, Adelaide, South Australia, Australasian Society of Diagnostic Genomics (ASDG) 2019Read More
November 5, 2018press